- The stock price of Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA) increased by over 35% pre-market today. This is why.
The stock price of Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA) – a global healthcare leader developing and producing patented Microcyn technology-based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, dermatological conditions, and disinfectant use – increased by over 35% pre-market today. Investors are responding positively to Sonoma Pharmaceuticals and its partner the MicroSafe Group DMCC received EPA approval for Nanocyn as a hospital-grade disinfectant in the United States.
Nanocyn, which is manufactured by Sonoma using its patented Microcyn Technology, is a ready-to-use hard-surface disinfectant that may reduce the risk of infection by treating hard, non-porous surfaces, making it especially useful in high-risk areas such as hospitals, schools, mass transit, and care facilities. The Nanocyn hospital-grade disinfectant is currently sold by MicroSafe Group in Europe, the Middle East/West Africa, and Australia.
Plus Nanocyn has been proven to kill a variety of bacteria like Staphylococcus aureus and Pseudomonas aeruginosa, and has a 30-second kill time for many viruses, including norovirus, on hard non-porous surfaces. In May 2020, Nanocyn was entered into the Australian Register of Therapeutic Goods (ARTG) for use against SARS-CoV-2 (COVID-19). Nanocyn utilizes Sonoma’s patented Microcyn technology which has a long, proven record of significantly reducing numerous bacteria, viruses, fungi, and spores on many surfaces. For more information see www.sonomapharma.com/literature/.
The EPA approval process was a coordinated effort by Sonoma and MicroSafe Group. And MicroSafe Group managed and financed the regulatory process with the EPA in exchange for non-exclusive rights to distribute Nanocyn in the United States. Sonoma provided expertise and manufactured the required product samples.
“The MicroSafe Group is very pleased with the EPA approval of Nanocyn hospital-grade disinfectant, known as MicroSafe® disinfectant in Europe, the Middle East/West Africa, and Australia. The EPA approval validates over 20 years of research, development, and independent testing that determines the unique stability and efficacy of Microcyn Technology, a revolution in stable HOCl. Furthermore, Nanocyn’s extraordinarily low toxicity profile as categorized by the EPA (lowest Category IV per 40 CFR 156.62) means that the product does not have special handling or disposal requirements. These features, in combination with its impressive kill time of viruses on treated hard non-porous surfaces, may make it a game-changer in the realm of infection control.”
– Safwan Abdallah, COO of the MicroSafe Group
“We are excited to bring our successful partnership with MicroSafe Group to the United States. We believe Nanocyn hospital-grade disinfectant has countless applications due to its efficacy and safety profile, and we are eager to play a role to help curb the spread of infectious disease here in the United States and globally.”
– Amy Trombly, CEO of Sonoma
Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.